Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition-Reference-Cited by-同舟云学术

Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition

Published:2021-01 Issue:2 Volume:13 Page:129-144
ISSN:1750-1911
Container-title:Epigenomics
language:en
Short-container-title:Epigenomics

Author:

Matissek Stephan J¹^ORCID,Han Weiguo¹^ORCID,Karbalivand Mona¹^ORCID,Sayed Mohamed¹^ORCID,Reilly Brendan M¹^ORCID,Mallat Shayna¹,Ghazal Shimaa M¹^ORCID,Munshi Manit²³,Yang Guang²³^ORCID,Treon Steven P²³^ORCID,Walker Sarah R¹^ORCID,Elsawa Sherine F¹^ORCID

Affiliation:

1. Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, 03824, USA

2. Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, 02215, USA

3. Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA

Abstract

Aim: Waldenström macroglobulinemia (WM) is a low-grade B-cell lymphoma characterized by overproduction of monoclonal IgM. To date, there are no therapies that provide a cure for WM patients, and therefore, it is important to explore new therapies. Little is known about the efficiency of epigenetic targeting in WM. Materials & methods: WM cells were treated with BET inhibitors (JQ1 and I-BET-762) and venetoclax, panobinostat or ibrutinib. Results: BET inhibition reduces growth of WM cells, with little effect on survival. This finding was enhanced by combination therapy, with panobinostat (LBH589) showing the highest synergy. Conclusion: Our studies identify BET inhibitors as effective therapy for WM, and these inhibitors can be enhanced in combination with BCL2 or histone deacetylase inhibition.

Funder

International Waldenstrom Macrglobulinemia Foundation and Leukemia & Lymphoma Society

Publisher

Future Medicine Ltd

Subject

Cancer Research,Genetics

Link

https://www.futuremedicine.com/doi/pdf/10.2217/epi-2020-0189

Reference63 articles.

1. Waldenström macroglobulinemia: What a hematologist needs to know

2. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

3. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia